Quinupristin-dalfopristin is a streptogramin antibiotic combination with activity against vancomycin-resistant Enterococcus faecium (VREF), but emergence of resistance has been recently reported. We studied the activity of quinupristin-dalfopristin against two clinical strains of VREF (12311 and 12366) in an in vitro pharmacodynamic model with simulated endocardial vegetations (SEVs) to determi...

Quinupristin/dalfopristin displays in-vitro bacteriostatic activity against all Legionella spp. (MICs = 0.06-2 mg/L), with Legionella pneumophila usually being at least two-fold more sensitive to quinupristin/dalfopristin than Legionella bozemanii, Legionella dumoffii, Legionella gormanii and Legionella micdadei (MIC = 0.06-2 vs 1-2 mg/L, respectively). Against Legionella spp., quinupristin/dal...

BACKGROUND Virginiamycin use in poultry selects for Enterococcus faecium with cross-resistance to quinupristin-dalfopristin, a drug for vancomycin-resistant E. faecium in humans. We conducted an epidemiologic study of poultry exposures as risk factors for human carriage of quinupristin-dalfopristin-resistant E. faecium. METHODS Rectal or fecal samples for E. faecium testing were obtained from...

Using checkerboard and time-kill assays, we evaluated the in vitro activity of quinupristin-dalfopristin (RP 59500) alone and in combination with five other antimicrobial agents against 12 clinical strains of vancomycin-resistant Enterococcus faecium (VREF). In time-kill studies, six VREF strains exhibited synergism with the combination of quinupristin-dalfopristin and doxycycline and three exh...

The occurrence of resistance to the streptogramin quinupristin-dalfopristin in Enterococcus faecium isolates from chickens on the Eastern Seaboard, was evaluated. Quinupristin-dalfopristin resistance was found in 51 to 78% of E. faecium isolates from the food production environment. The high level of resistance in this organism suggests that this reservoir of resistance may compromise the thera...

scan revealed anterior and posterior cerebral artery infarctions of to determine its safety and the minimum dosage needed to eradicate VREF from the CSF. unknown origin. Electroencephalography was performed, which detected no brain activity, and the decision was made to withdraw Gretchen M. Tush, Scott Huneycutt, Amy Phillips, life support. A CSF culture performed on a specimen obtained and Joh...

The activity of quinupristin/dalfopristin was compared with that of other widely used antibiotics against 355 strains isolated from patients with endocarditis. MICs were determined by a standard agar dilution method. Quinupristin/dalfopristin was inhibitory at 1 mg/L for all coagulase-negative staphylococci (n = 36) and for the majority of Staphylococcus aureus strains (n = 87). The activity of...

STUDY OBJECTIVE To evaluate risk factors for the development of arthralgias or myalgias associated with quinupristin-dalfopristin. DESIGN Retrospective chart review and case-control analysis. SETTING An 850-bed tertiary care medical center. PATIENTS All adult and pediatric patients who had received quinupristin-dalfopristin through either a compassionate-use protocol (February 1996-Octobe...

Quinupristin-dalfopristin is a streptogramin combination active against multiply resistant Enterococcus faecium. Among 45 E. faecium isolated from patients in various French hospitals, only two strains were intermediate (MIC = 2 microgram/ml) and one, E. faecium HM1032, was resistant (MIC = 16 microgram/ml) to quinupristin-dalfopristin, according to British Society for Antimicrobial Chemotherap...

Twenty-eight quinupristin-dalfopristin-resistant isolates of Enterococcus faecium from hospital patients and nonhuman sources in European countries were studied. High-level resistance (MICs, >/=32 microg/ml) was associated with the presence of vat(E) (satG) (14 isolates ¿50%) or vat(D) (satA) (6 isolates ¿21%). These genes were not detected in eight (29%) isolates with lower levels of quinupris...